The most important number in the October BPC-157 review is not a percentage improvement. It is the size and structure of the human evidence the authors could include: three studies, with 30 participants in total. That is an evidence inventory, not a new 30-person clinical trial.
The PubMed abstract of Poolton, Minett and Kazmi’s systematic review reports searches of Embase, PubMed, the Cochrane Library and ClinicalTrials.gov through June 1, 2026. Published October 8 in Acta Orthopaedica Belgica, it used a before–after study quality tool and GRADE to assess the evidence. Our extraction is of the abstract, not a full-text or individual-patient-data audit.
Three studies, three different questions
The included studies were a retrospective intra-articular knee-pain study with 16 participants, a retrospective intravesical interstitial-cystitis pilot with 12, and a prospective intravenous safety pilot with two. Adding the numbers does not turn these different indications and routes into one generalizable treatment population. Nor does it establish evidence for an oral or subcutaneous service offered by a practice.
The abstract reports symptom improvement in most participants and no treatment-related adverse events. It also judges every included study to be poor methodological quality and the overall certainty very low, citing serious risk of bias, indirectness and imprecision. Both halves belong in an honest account. Dropping the limitations while retaining the positive symptoms would reverse the practical meaning of the review.
No reported adverse events is a narrow finding
The absence of a reported treatment-related event in these small studies is not a demonstration of population safety. It cannot settle uncommon harms, longer-term effects or the quality of a different preparation. The review’s authors conclude that clinical use should be confined to ethically approved, regulated, high-quality trials. That is their conclusion; this article does not independently adjudicate an individual patient’s treatment.
There is an additional date boundary. The review searched through June 1, although it appeared in October. It is not a search of everything published through our October 29 annual-review cutoff. A registered study or later publication must be assessed separately rather than silently folded into this denominator.
Why the FDA materials can describe a different evidence set
The July FDA presentation says there was insufficient clinical safety information for BPC-157 free base and acetate; PDF page 55 discusses the proposed routes and limited information in rectal-enema studies. That regulatory assessment addresses different proposed uses and evidence boundaries from the October review’s included human studies. The two documents should not be presented as competing universal counts of all human exposure.
For a medspa owner or RN evaluating a claim, the first questions are therefore precise: which preparation, route, indication, population and design support it? A review discussing knee pain, bladder symptoms and a two-person IV pilot cannot be compressed into “clinically proven recovery.” The defensible annual-review finding is that interest has outpaced robust clinical validation—not that these abstracts establish a treatment protocol.
Evidence record
Event date: 2026-10-08. Source review: 2026-10-29. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
- Poolton et al., systematic-review abstract; October 8, 2026 ↗
- FDA July 23 presentation; PDF pages 54–55 ↗
Revision history
29 October 2026: expanded against the specifically cited source passages. Source review is not qualified clinical or legal review. Report a proposed correction through Contact us; do not include patient data.